Clinical Trial Update: Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating intravitreal tissue plasminogen activator (tPA) and C3F8 gas for submacular hemorrhage complicating neovascular age-related macular d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exudative Macular Degeneration
• Retinal Hemorrhage

Drugs mentioned

• C3F8 (perfluoropropane)
• intravitreal tPA (tissue plasminogen activator)

Snippet

Sponsor: King's College Hospital NHS Trust | Conditions: Exudative Macular Degeneration, Retinal Hemorrhage | Phase 2, Phase 3 | Status: COMPLETED